Bruker Corporation announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed.

布鲁克公司宣布收购位于奥地利因斯布鲁克的生物科学公司biocrates life sciences ag，财务条款尚未披露。

biocrates is a leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits cover over 1,000+ metabolites from more than 40 metabolite classes, and the biocrates metabolomics technology platform combines innovative sample preparation, metabolite identification, and data analysis..

biocrates 是基于质谱 (MS) 的定量代谢物和脂质分析试剂盒、检测、软件和服务的领导者，使标准化代谢组学能够普及到全球实验室。biocrates 试剂盒涵盖来自 40 多个代谢物类别的 1,000 多种代谢物，其代谢组学技术平台结合了创新的样品制备、代谢物鉴定和数据分析。

The acquisition of biocrates further enhances Bruker’s MS-based metabolomics solutions. It also supports Bruker’s expansion into multiomics solutions, including instruments, reagents, software, and research services, building on the prior acquisitions of proteomics kits, software and services companies PreOmics and Biognosys..

生物标志物的获取进一步增强了布鲁克基于质谱（MS）的代谢组学解决方案。这也支持了布鲁克向多组学解决方案的扩展，包括仪器、试剂、软件和研究服务，建立在先前收购的蛋白质组学试剂盒、软件和服务公司PreOmics和Biognosys的基础之上。

Dr. Oliver Rinner, Bruker’s Vice President for Enabling Multiomics Solutions and founder and CEO of Biognosys stated: “Multiomics is the cornerstone for the future of life sciences, biopharma R&D and clinical research, and biocrates adds key metabolomics solutions to the Bruker portfolio. With our services, software and kits for high-end proteomics and metabolomics we can now support customers with a truly integrated multiomics approach.”.

布鲁克赋能多组学解决方案副总裁、Biognosys创始人兼首席执行官Oliver Rinner博士表示：“多组学是生命科学、生物制药研发和临床研究未来发展的基石，而biocrates为布鲁克的产品组合增添了关键的代谢组学解决方案。通过我们针对高端蛋白质组学和代谢组学的服务、软件和试剂盒，我们现在能够以真正整合的多组学方法为客户提供支持。”

'Our acquisition of biocrates represents a pivotal step in our ambitious metabolomics and lipidomics growth plans,' said Matthew Lewis, Ph.D., Bruker Vice President, Metabolomics & Lipidomics. 'By leveraging biocrates' expertise in quantitation and workflow automation, we accelerate the impact of MS-based omics to revolutionize and advance a shared multiomics vision.'.

“我们对生物克拉特斯的收购代表了我们在雄心勃勃的代谢组学和脂质组学增长计划中的关键一步，”布鲁克副总裁、代谢组学与脂质组学博士马修·刘易斯表示。“通过利用生物克拉特斯在定量和工作流程自动化方面的专业知识，我们加速了基于质谱的组学影响，以革新并推进共同的多组学愿景。”

Moritz Seuster, biocrates’ CEO, added: “Joining Bruker is a major milestone and a strong validation of our team’s hard work and vision. What makes this partnership so powerful is our shared passion for multiomics technologies and biocrates’ continued commitment to supporting and innovating across multiple MS technologies and vendors.

莫里茨·塞乌斯特，生物晶体公司的首席执行官补充道：“加入布鲁克是一个重要的里程碑，也是对我们团队辛勤工作和愿景的有力验证。这次合作的强大之处在于我们对多组学技术的共同热情，以及生物晶体公司继续致力于支持和创新多种质谱技术和供应商。”

With Bruker we’re poised to scale our impact while staying true to our mission to make omics quantitative, reproducible and easily accessible. We’re deeply thankful to our employees, customers, and partners who made this possible.”.

与布鲁克合作，我们准备在保持使组学定量、可重复且易于获取的使命的同时扩大我们的影响力。我们深深感谢我们的员工、客户和合作伙伴，是他们使之成为可能。

https://www.bionity.com/en/news/1186413/bruker-announces-acquisition-of-biocrates.html

https://www.bionity.com/zh/news/1186413/布鲁克宣布收购生物标志物.html

Thermo Fisher Scientific to Acquire QIAGEN

赛默飞世尔科技将收购凯杰公司

Read news

读新闻

Most read news

最受关注的新闻

1

1

Artificial sweeteners cause confusion in the brain

人工甜味剂导致大脑混乱

2

2

Chronic Sleep Disorder or Busy Whiling Away Time?

慢性睡眠障碍还是忙碌地消磨时间？

3

3

Identifying pathogens within minutes instead of days

在几分钟内而不是几天内识别病原体

4

4

Bacterium Produces “Organic Dishwashing Liquid” to Degrade Oil

细菌产生“有机洗洁精”来降解油污

5

5

Highly Reactive Catalyst Enables Labeling of Biologically Active Compounds

高活性催化剂助力生物活性化合物的标记

Topics

主题

mass spectrometry

质谱分析

metabolomics

代谢组学

lipidomics

脂质组学

aquisition

获取

takeovers

接管

Show all

显示全部

Show less

显示更少

Organizations

组织机构

Bruker

用户

Biocrates Life Sciences

Biocrates生命科学